Investigating how a protein affects prostate cancer progression
Hsp60 Regulation of Prostate Cancer Progression
This study is looking at how a protein called HSP60 affects the growth of aggressive prostate cancer, and it hopes to find out if blocking this protein could help patients, especially those with more serious forms of the disease, by making the cancer cells die and slowing down tumor growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10914839 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of heat shock protein 60 (HSP60) in the progression of prostate cancer. It examines how HSP60 contributes to aggressive and treatment-resistant forms of the disease by analyzing genetically-engineered mouse models and human tumor samples. The study aims to determine whether targeting HSP60 could provide therapeutic benefits for patients with prostate cancer, particularly those with higher Gleason Scores. By silencing HSP60 or inhibiting its function, researchers hope to induce cancer cell death and reduce tumor growth.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with aggressive or castration-resistant prostate cancer.
Not a fit: Patients with early-stage or non-aggressive prostate cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target aggressive prostate cancer, improving patient outcomes.
How similar studies have performed: Other research has shown promising results in targeting mitochondrial proteins for cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Chandra, Dhyan — Roswell Park Cancer Institute Corp
- Study coordinator: Chandra, Dhyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.